JP2019524883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524883A5 JP2019524883A5 JP2019529309A JP2019529309A JP2019524883A5 JP 2019524883 A5 JP2019524883 A5 JP 2019524883A5 JP 2019529309 A JP2019529309 A JP 2019529309A JP 2019529309 A JP2019529309 A JP 2019529309A JP 2019524883 A5 JP2019524883 A5 JP 2019524883A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cyclyl
- heterocyclyl
- group
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610647295.0A CN107698593A (zh) | 2016-08-09 | 2016-08-09 | 作为fgfr抑制剂的杂环化合物 |
| CN201610647295.0 | 2016-08-09 | ||
| PCT/CN2017/094620 WO2018028438A1 (zh) | 2016-08-09 | 2017-07-27 | 作为fgfr抑制剂的杂环化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524883A JP2019524883A (ja) | 2019-09-05 |
| JP2019524883A5 true JP2019524883A5 (enExample) | 2020-07-16 |
| JP6959663B2 JP6959663B2 (ja) | 2021-11-02 |
Family
ID=61162708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529309A Expired - Fee Related JP6959663B2 (ja) | 2016-08-09 | 2017-07-27 | Ｆｇｆｒ阻害剤としての複素環化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10752631B2 (enExample) |
| EP (1) | EP3498706A4 (enExample) |
| JP (1) | JP6959663B2 (enExample) |
| KR (1) | KR20190035870A (enExample) |
| CN (2) | CN107698593A (enExample) |
| CA (1) | CA3032921A1 (enExample) |
| WO (1) | WO2018028438A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102945203B1 (ko) | 2017-05-08 | 2026-03-31 | 시애틀 프로젝트 코포레이션 | 알파바이러스 신생항원 벡터 |
| KR20210090650A (ko) | 2018-11-07 | 2021-07-20 | 그릿스톤 바이오, 인코포레이티드 | 알파바이러스 신생항원 벡터 및 인터페론 억제제 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| JP2022533939A (ja) * | 2019-05-17 | 2022-07-27 | キネート バイオファーマ インク． | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
| SG11202113187WA (en) | 2019-05-30 | 2021-12-30 | Gritstone Bio Inc | Modified adenoviruses |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4161657A1 (en) * | 2020-06-05 | 2023-04-12 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| CN116057045B (zh) | 2020-06-05 | 2026-06-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶抑制剂 |
| IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
| CN112480109B (zh) * | 2020-11-16 | 2022-04-01 | 浙江大学 | 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途 |
| MX2023008186A (es) * | 2021-01-12 | 2023-07-18 | Beijing Innocare Pharma Tech Co Ltd | Proceso para preparar (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida. |
| CN114853739B (zh) * | 2021-02-03 | 2023-09-22 | 药雅科技(上海)有限公司 | 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途 |
| CN115043832B (zh) * | 2021-03-08 | 2023-08-22 | 药雅科技(上海)有限公司 | 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途 |
| CN120051471A (zh) * | 2022-10-18 | 2025-05-27 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1981890A2 (en) * | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
| AU2013210403B2 (en) | 2012-01-19 | 2016-01-14 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| JP6378308B2 (ja) * | 2013-03-13 | 2018-08-22 | ボストン バイオメディカル， インコーポレイテッド | がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体 |
| DK3023100T3 (da) * | 2013-07-18 | 2019-05-27 | Taiho Pharmaceutical Co Ltd | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer |
| JP6084292B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| CN104341425B (zh) * | 2013-08-08 | 2018-11-02 | 上海医药集团股份有限公司 | 氘代乙炔衍生物、其药物组合物及应用 |
| RU2677884C2 (ru) * | 2013-09-30 | 2019-01-22 | Гуанчжоу Иннокэа Фарма Тек Ко., Лтд. | Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний |
| EP3184521B1 (en) * | 2014-08-19 | 2021-10-06 | Shanghai Haihe Pharmaceutical Co., Ltd. | Indazole compounds as fgfr kinase inhibitors, preparation and use thereof |
-
2016
- 2016-08-09 CN CN201610647295.0A patent/CN107698593A/zh active Pending
-
2017
- 2017-07-27 WO PCT/CN2017/094620 patent/WO2018028438A1/zh not_active Ceased
- 2017-07-27 CN CN201780045675.XA patent/CN109715626B/zh active Active
- 2017-07-27 KR KR1020197006637A patent/KR20190035870A/ko not_active Ceased
- 2017-07-27 US US16/324,189 patent/US10752631B2/en not_active Expired - Fee Related
- 2017-07-27 JP JP2019529309A patent/JP6959663B2/ja not_active Expired - Fee Related
- 2017-07-27 EP EP17838568.8A patent/EP3498706A4/en not_active Withdrawn
- 2017-07-27 CA CA3032921A patent/CA3032921A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014193925A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2015520140A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| JP2017071634A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2016505512A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| CN109715626A (zh) | 作为fgfr抑制剂的杂环化合物 | |
| JP2020097577A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2020532545A5 (enExample) |